Mechanisms and management of hypertensive heart disease: From left ventricular hypertrophy to heart failure

Medical Clinics of North America

Volumn 88, Issue 5, 2004, Pages 1257-1271

  Izzo Jr , Joseph L ^a,d   Gradman, Alan H ^b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b WESTERN PENNSYLVANIA HOSPITAL   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEMOGRAPHY; DIASTOLE; DISEASE CLASSIFICATION; DISEASE MARKER; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WORK; HEMODYNAMICS; HUMAN; HYPERTENSION; MEDICAL SOCIETY; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAUSE OF DEATH; DIASTOLE; DISEASE PROGRESSION; DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; PATIENT SELECTION; PRACTICE GUIDELINES; PRIMARY PREVENTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 4444252228     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.06.002     Document Type: Review

References (70)

1. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 Express JAMA 289 2003 2560 2572
2. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
3. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, and G.S. Francis ACC/AHA guidelines for the evaluation and management of chronic HF in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 104 2001 2996 3007
4. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
5. V.L. Burt, P. Whelton, E.J. Roccella, C. Brown, J.A. Cutler, and M. Higgins Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991 Hypertension 25 1995 305 313
6. D. Levy, K.M. Anderson, D.D. Savage, W.B. Kannel, J.C. Christiansen, and W.P. Castelli Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. the Framingham Heart Study Ann Intern Med 108 1988 7 13
7. P. Rheeder, R.P. Stolk, A. Mosterd, H.A. Pols, A. Hofman, and D.E. Grobbee Insulin resistance syndrome and left ventricular mass in an elderly population (the Rotterdam Study) Am J Cardiol 84 1999 233 236 A239
8. A. Mosterd, R.B. D'Agostino, H. Silbershatz, P.A. Sytkowski, W.B. Kannel, and D.E. Grobbee Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989 N Engl J Med 340 1999 1221 1227
9. D.D. Savage, R.J. Garrison, W.B. Kannel, D. Levy, S.J. Anderson, and J. Stokes III The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study Circulation 75 1 Pt 2 1987 I26 I33
10. E.D. Frohlich Pathogenesis of hypertensive left ventricular hypertrophy and diastolic dysfunction Izzo J.L. Jr. Black H.R. Hypertension primer 3rd edition 2003 American Heart Association Dallas (TX) 175 177
11. R. Antikainen, T. Grodzicki, A.J. Palmer, D.G. Beevers, E.C. Coles, and J. Webster The determinants of left ventricular hypertrophy defined by Sokolow-Lyon criteria in untreated hypertensive patients J Hum Hypertens 17 2003 159 164
12. W.S. Post, M.N. Hill, C.R. Dennison, J.L. Weiss, G. Gerstenblith, and R.S. Blumenthal High prevalence of target organ damage in young, African American inner-city men with hypertension J Clin Hypertens 5 1 2003 24 30
13. W.B. Kannel, and P.W.F. Wilson Cardiovascular risk factors and hypertension Izzo J.L. Jr. Black H.R. Hypertension primer 3rd edition 2003 American Heart Association Dallas (TX) 235 238
14. B.A. Vakili, P.M. Okin, and R.B. Devereux Prognostic significance of left ventricular hypertrophy Am Heart J 141 2001 334 341
15. W.S. Aronow, and C. Ahn Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure J Am Geriatr Soc 46 1998 1280 1281
16. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study Ann Intern Med 110 1989 101 107
17. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
18. R.S. Vasan, E.J. Benjamin, and D. Levy Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective J Am Coll Cardiol 26 1995 1565 1574
19. A.W. Haider, M.G. Larson, S.S. Franklin, and D. Levy Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study Ann Intern Med 138 2003 10 16
20. M. Wendelin-Saarenhovi, R.E. Isoaho, J.J. Hartiala, H.Y. Helenius, S.L. Kivela, and M.K. Lopponen Ambulatory blood pressure and left ventricular mass in older age Scand J Clin Lab Invest 62 2002 569 577
21. G. Mancia, A. Zanchetti, E. Agabiti-Rosei, G. Benemio, R. De Cesaris, and R. Fogari Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation Circulation 95 1997 1464 1470
22. G. de Simone, V. Palmieri, J.N. Bella, A. Celentano, Y. Hong, and A. Oberman Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study J Hypertens 20 2002 323 331
23. V. Palmieri, J.N. Bella, M.J. Roman, E. Gerdts, V. Papademetriou, and K. Wachtell Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study J Hypertens 21 2003 781 787
24. M.J. Roman, A. Ganau, P.S. Saba, R. Pini, T.G. Pickering, and R.B. Devereux Impact of arterial stiffening on left ventricular structure Hypertension 36 2000 489 494
25. H.C. Gerstein, J.F. Mann, J. Pogue, S.F. Dinneen, J.P. Halle, and B. Hoogwerf Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The Study Investigators Diabetes Care 23 Suppl 2 2000 B35 B39
26. G. Dell'omo, D. Giorgi, V. Di Bello, M. Mariani, and R. Pedrinelli Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men J Int Med 254 2003 76 84
27. J.M. Sorof, J. Turner, D.S. Martin, K. Garcia, Z. Garami, and A.V. Alexandrov Cardiovascular risk factors and sequelae in hypertensive children identified by referral versus school-based screening Hypertension 43 2004 214 218
28. N. Ferrara, G. Furgi, G. Longobardi, A. Nicolino, D. Acanfora, and D. Leosco Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension J Hum Hypertens 9 1995 581 587
29. H. Gunduz, R. Akdemir, E. Binak, A. Tamer, and C. Uyan Relation between stage of left ventricular diastolic dysfunction and QT dispersion Acta Cardiol 58 2003 303 308
30. J.M. McLenachan, and H.J. Dargie Left ventricular hypertrophy as a factor in arrhythmias and sudden death Am J Hypertens 2 1989 128 131
31. K.F. Adams Jr., and F. Zannad Clinical definition and epidemiology of advanced heart failure Am Heart J 135 6 Pt 2 Suppl 1998 S204 S215
32. R.B. Devereux Management of hypertensive patients with left ventricular hypertrophy and diastolic dysfunction Izzo J.L. Jr. Black H.R. Hypertension primer 3rd edition 2003 American Heart Association Dallas (TX) 460 463
33. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, and B. Olofsson CHARM Investigators Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
34. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, and E.L. Michelson CHARM Investigators Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
35. M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, and E.L. Michelson CHARM Investigators Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 9386 2003 759 766
36. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, and J.J. McMurray CHARM Investigators Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
37. G.F. Mitchell, Y. Lacourciere, J.P. Ouellet, J.L. Izzo Jr., J. Neutel, and L.J. Kerwin Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship Circulation 108 2003 1592 1598
38. M.M. Laks, and F. Morady Norepinephrine - the myocardial hypertrophy hormone Am Heart J 91 1976 674 675
39. B. Waeber, and H.R. Brunner Cardiovascular hypertrophy: role of angiotensin II and bradykinin J Cardiovasc Pharmacol 27 Suppl 2 1996 S36 S40
40. S. Ichihara, T. Senbonmatsu, E.J. Price, T. Ichiki, F.A. Gaffney, and T. Inagami Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension Circulation 104 2001 346 351
41. R.E. Schmieder, and M.P. Schlaich Comparison of therapeutic studies on regression of left ventricular hypertrophy Adv Exp Med Biol 432 1997 191 198
42. Y. Sun, and K.T. Weber Cardiac remodeling by fibrous tissue: role of local factors and circulating hormones Ann Med 30 Suppl 1 1998 3 8
43. K.T. Weber Metabolic responses of extracellular matrix in tissue repair Ann Med 29 1997 333 338
44. D.K. Arnett, Y. Hong, J.N. Bella, A. Oberman, D.W. Kitzman, and P.N. Hopkins Sibling correlation of left ventricular mass and geometry in hypertensive African-Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network Am J Hypertens 14 2001 1226 1230
45. M. Galderisi, A. Celentano, M. Garofalo, P. Tammaro, M. Crivaro, and O. de Divitiis Parental left ventricular hypertrophy predicts Doppler-derived diastolic filling in young offspring of hypertensive subjects J Hypertens Suppl 11 Suppl 5 1993 S76 S77
46. D.K. Arnett, R.B. Devereux, D. Kitzman, A. Oberman, P. Hopkins, and L. Atwood Linkage of left ventricular contractility to chromosome 11 in humans: the HyperGEN Study Hypertension 38 2001 767 772
47. D.W. Kitzman, W.C. Little, P.H. Brubaker, R.T. Anderson, W.G. Hundley, and C.T. Marburger Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure JAMA 288 2002 2144 2150
48. R.S. Williams Apoptosis and heart failure N Engl J Med 341 1999 759 760
49. P. Rerkpattanapipat, W.G. Hundley, K.M. Link, P.H. Brubaker, C.A. Hamilton, and S.N. Darty Relation of aortic distensibility determined by magnetic resonance imaging in patients > or = 60 years of age to systolic heart failure and exercise capacity Am J Cardiol 90 2002 1221 1225
50. K.T. Weber Cardioreparation in hypertensive heart disease Hypertension 38 3 Pt 2 2001 588 591
51. C.U. Chae, M.A. Pfeffer, R.J. Glynn, G.F. Mitchell, J.O. Taylor, and C.H. Hennekens Increased pulse pressure and risk of heart failure in the elderly JAMA 281 1999 634 639
52. G.F. Mitchell, J.C. Tardif, J.M. Arnold, G. Marchiori, T.X. O'Brien, and M.E. Dunlap Pulsatile hemodynamics in congestive heart failure Hypertension 38 2001 1433 1439
53. J.N. Cohn Left ventricle and arteries: structure, function, hormones, and disease Hypertension 37 2 Part 2 2001 346 349
54. E.D. Frohlich Hypertension, left ventricular hypertrophy, and coronary flow reserve Adv Exp Med Biol 432 1997 253 262
55. P.V. Vaitkevicius, J.L. Fleg, J.H. Engel, F.C. O'Connor, J.G. Wright, and L.E. Lakatta Effects of age and aerobic capacity on arterial stiffness in healthy adults Circulation 88 4 Pt 1 1993 1456 1462
56. J.A. Staessen, J.G. Wang, L. Thijs, and R. Fagard Overview of the outcome trials in older patients with isolated systolic hypertension J Hum Hypertens 13 1999 859 863
57. M. Pahor, B.M. Psaty, M.H. Alderman, W.B. Applegate, J.D. Williamson, and C. Cavazzini Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials Lancet 356 2000 1949 1954
58. The ALLHAT Officers Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
59. J. Mathew, P. Sleight, E. Lonn, D. Johnstone, J. Pogue, and Q. Yi Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril Circulation 104 2001 1615 1621
60. P. Verdecchia, F. Angeli, C. Borgioni, R. Gattobigio, G. de Simone, and R.B. Devereux Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis Am J Hypertens 16 11 Pt 1 2003 895 899
61. R. Fagard, P. Lijnen, J. Staessen, L. Thijs, and A. Amery Mechanical and other factors relating to left ventricular hypertrophy Blood Press Suppl 1 1994 5 10
62. P. Sleight, S. Yusuf, J. Pogue, R. Tsuyuki, R. Diaz, and J. Probstfield Blood-pressure reduction and cardiovascular risk in HOPE study Lancet 358 2001 2130 2131
63. P. Svensson, U. de Faire, P. Sleight, S. Yusuf, and J. Ostergren Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy Hypertension 38 2001 E28 E32
64. P.M. Okin, R.B. Devereux, S. Jern, S.E. Kjeldsen, S. Julius, and M.S. Nieminen Losartan Intervention for Endpoint Reduction in Hypertension Study I. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study Circulation 108 2003 684 690
65. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, and U. de Faire Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
66. R.B. Devereux, B. Dahlof, S.E. Kjeldsen, S. Julius, P. Aurup, and G. Beevers Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial Ann Intern Med 139 2003 169 177
67. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr., and T.E. Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial N Engl J Med 327 1992 669 677
68. Studies of Left Ventricular Dysfunction (SOLVD) Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction N Engl J Med 327 1992 685 691
69. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, and A.P. Maggioni Valsartan in Acute Myocardial Infarction Trial I. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
70. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension JAMA 265 1991 3255 3264